结核病生物标志物的药物遗传变异性在秘鲁本土和混血人口中
Luis Jaramillo-Valverde1,2,3, Kelly S Levano1,4, David D Tarazona1
1Laboratorio de Biotecnología y Biología Molecular, Instituto Nacional de Salud, Lima, Peru.
Pharmacology research & perspectives
|April 26, 2024
概括
在NAT2和CYP2E1的遗传变异影响药物诱导肝损伤 (DILI) 风险从秘鲁人结核病治疗. 这项研究确定了与混血儿和土著个体中DILI风险增加或减少相关的特定类型,有助于个性化治疗策略.
科学领域:
- 药物基因组学 药物基因组学
- 临床药理学 临床药理学
- 遗传流行病学遗传流行病学
背景情况:
- 秘鲁的结核病 (TB) 治疗因药物不良反应而面临挑战,主要是药物诱导的肝损伤 (DILI).
- 伊索尼亚 (INH) 是一线结核病药物,是DILI的主要原因,由N-乙转移酶-2 (NAT2) 和细胞染色体P450 2E1 (CYP2E1) 代谢.
- 关于影响秘鲁原住民和混血儿人口DILI风险的遗传因素的数据有限.
研究的目的:
- 确定NAT2和CYP2E1基因型在秘鲁本土和混血人口中的患病率.
- 调查这些基因型与抗结核药物DILI风险之间的关联.
主要方法:
- 来自472名混血 (利马) 和本地 (秘鲁南部) 参与者的遗传数据的横截面分析.
- 分子测试和生物信息分析以确定NAT2代谢器状态 (快速,中间,缓慢) 和CYP2E1基因型 (c1/c1,c1/c2,c2/c2).
- 对NAT2单核酸多态 (SNP) 的链接不平衡的估计.
主要成果:
- 在混血儿中确定了36个NAT2单元类型,在土著人中确定了6个.
- 混血族人群显示NAT2*5B和NAT2*7B的单质类型与DILI风险相关.
- 本地人群显示NAT2*5G和NAT2*13A亚型与降低DILI风险相关.
- CYP2E1的c1/c1和c1/c2基因型分别在土著人和混血儿中最常见.
- 在本地人和混血儿群体之间观察到NAT2 SNPs的明显链接不平衡模式.
结论:
- 在秘鲁本土人和混血儿群体中报告的NAT2和CYP2E1等位基因的流行率.
- 确定了与不同秘鲁族群中不同DILI风险相关的特定NAT2单元型.
- 结果为在秘鲁开发个性化结核病控制治疗策略提供了基础.
相关概念视频
01:26Pulmonary Tuberculosis IV
140
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
140
01:28Pulmonary Tuberculosis V
178
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
178
01:29Pulmonary Tuberculosis I
241
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
241
01:31Pulmonary Tuberculosis III
324
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
324